IL6 and congenital rubella syndrome: In this work, we developed the proof of concept for a rapid IL-6 VFA with a wide reportable range that supports its use in a broad spectrum of diseases, including RA, COVID-19-induced CRS, CAR-T therapy-induced CRS, sepsis disease activity, and other inflammatory diseases.